SCHEDULE 13G/A: Corcept Therapeutics CEO Joseph Belanoff Discloses Significant Beneficial Ownership Stake

Corcept Therapeutics Incorporated's CEO, Dr. Joseph K. Belanoff, has filed an amendment to his Schedule 13G, detailing his beneficial ownership of 6.3% of the company's Common Stock as of December 31, 2024.

Summary

• Dr. Joseph K. Belanoff, Chief Executive Officer of Corcept Therapeutics Incorporated, reported beneficial ownership of 6,822,335 shares of the company's Common Stock.
• This ownership represents 6.3% of the total class of Common Stock.
• The total beneficial ownership consists of 3,022,335 shares of Common Stock directly held and 3,800,000 shares underlying stock options.
• The stock options are exercisable prior to March 1, 2025.
• Dr. Belanoff holds sole voting and dispositive power over the 3,800,000 shares derived from stock options.
• He holds shared voting and dispositive power over the 3,022,335 directly held shares of Common Stock.

Sentiment

Score: 7

Explanation: The filing indicates a substantial beneficial ownership stake by the CEO, including a large number of exercisable stock options. This generally signals management's confidence in the company's future performance and aligns their interests with shareholders, which is a positive indicator.

Positives

• The CEO, Dr. Joseph K. Belanoff, maintains a significant beneficial ownership stake of 6.3% in Corcept Therapeutics, indicating strong alignment with shareholder interests and confidence in the company's future.
• A substantial portion of his ownership (3,800,000 shares) is derived from stock options exercisable prior to March 1, 2025, suggesting these options are likely in-the-money or near-money, reflecting potential value for the holder.

Risks

• No specific risks related to the company's operations, financial health, or strategic direction are disclosed in this beneficial ownership report, as its scope is limited to the reporting person's shareholdings.

Future Outlook

This document, a Schedule 13G amendment, is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is a routine disclosure of beneficial ownership by a corporate insider, common across all publicly traded industries. It does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical or biotechnology sector.

Stakeholder Impact

• Shareholders may view the CEO's significant beneficial ownership as a positive sign of strong insider confidence and alignment of management interests with shareholder value creation.

Key Dates

Keywords

Corcept Therapeutics, Joseph K. Belanoff, Schedule 13G, Beneficial Ownership, Common Stock, Stock Options, SEC Filing, Insider Ownership